米氮平对改善青春期小鼠焦虑抑郁样行为的研究

doi:10.11852/zgetbjzz2021-1755

摘要/Abstract

摘要： 目的探讨不同浓度米氮平对慢性束缚应激导致的青春期小鼠焦虑、抑郁样行为的改善作用,为青春期情绪障碍的治疗提供研究资料。方法随机选取60只出生3~4 周龄雄性C57小鼠,模型组给予连续10 d(4 h/d)束缚应激(CRS),治疗组分别连续腹腔注射低浓度(15 mg/kg)或高浓度(30 mg/kg)米氮平(10 d)。分别采用矿场实验(OFT)检测焦虑样行为,悬尾实验(TST)和强迫游泳实验(FST)检测抑郁样行为,酶联免疫法检测血清米氮平水平。结果 OFT实验中,CRS小鼠在中央区停留时间为(106.1±36.64)s,低于对照组[(182.5±38.69)s](P<0.01),应用高浓度米氮平(30 mg/kg)后该时间延长至(186.1±23.43)s,接近正常水平。TST实验中,CRS组静止时间为(176.2±104.5)s,高于对照组[(71.05±36.4)s](P<0.01),应用高浓度米氮平(30 mg/kg)后时间缩短为(69.13±31.72)s(P>0.05)。FST实验中,CRS组的漂浮时间为(304.6±87.96)s,高于对照组[(196.2±72.6)s](P<0.01),应用高浓度米氮平(30 mg/kg)后,漂浮时间缩短为(188.8±49.05)s(P>0.05)。CRS导致小鼠血清NE[(34.52±9.03)pg/ml)]和5-HT[(44.42±16.55)ng/ml]水平低于正常小鼠(P<0.01),应用高浓度米氮平后恢复接近正常水平[NE:(105.93±21.42)pg/ml,5-HT:(133.56±32.31)ng/ml]。结论 CRS可以造成青春期小鼠抑郁和焦虑样情绪障碍,全身慢性应用高浓度米氮平可改善其焦虑和抑郁的症状。

关键词: 慢性束缚应激, 焦虑, 抑郁, 米氮平

Abstract: Objective To investigate the effects of different concentrations of mirtazapine on anxiety and depression like behavior induced by chronic restraint stress in adolescent mice, so as to provide data for the treatment of adolescent emotional disorders. Methods A total of 60 male C57 mice aged 3 - 4 weeks were randomly selected. The model group was under chronic restraint stress (CRS) 4 hours per day for 10 days. The treatment group was injected with low concentration (15 mg/kg) or high concentration (30 mg/kg) mirtazapine for 10 days. Anxiety like behavior was detected by open-field test (OFT), depression like behavior was detected by tail-suspension test (TST) and force swim test (FST), and serum mirtazapine level was detected by enzyme-linked immunosorbent assay. Results In the OFT experiment, the residence time of CRS mice in the central area was lower than that in the control group[(106.1±36.64)s vs. (182.5±38.69)s, P<0.01). After the application of high concentration mirtazapine (30 mg/kg), the time was extended to (186.1±23.43)s, which was close to the normal level. In the TST experiment, the resting time of CRS group was higher than that of control group[(176.2±104.5)s vs. (71.05±36.4)s, P<0.01]. After the application of high concentration mirtazapine (30 mg/kg), the time was shortened to (69.13±31.72)s (P > 0.05). In FST experiment, the floating time of CRS group was higher than that of control group[(304.6±87.96)s vs. (196.2±72.6)s, P<0.01]. After high concentration mirtazapine (30 mg/kg), the floating time was shortened to (188.8±49.05)s (P> 0.05). CRS resulted in that serum NE [(34.52±9.03)pg/ml] and 5-HT [(44.42±16.55)ng/ml] levels of mice in CRS group were lower than those of normal mice (P<0.01). After application of high concentration mirtazapine, it returned to the normal level (NE:(105.93±21.42)pg/mL,5-HT:(133.56±32.31)ng/mL. Conclusions CRS may lead to depression and anxiety like mood disorder in adolescent mice. Systemic chronic application of high concentration mirtazapine can improve the symptoms of anxiety and depression.

Key words: chronic restraint stress, anxiety, depression, mirtazapine

中图分类号:

R749.4

付佳蕾, 兰楠, 贾艺玮, 苟伟, 陈丽, 胡浩, 雷晓梅. 米氮平对改善青春期小鼠焦虑抑郁样行为的研究[J]. 中国儿童保健杂志, 2022, 30(5): 509-512.

FU Jia-lei, LAN Nan, JIA Yi-wei, GOU Wei, CHEN Li, HU Hao, LEI Xiao-mei. Effect of mirtazapine on anxiety depression-like behavior in adolescent mice[J]. Chinese Journal of Child Health Care, 2022, 30(5): 509-512.

参考文献

[1] 王瑞娜,田小娟. 根皮素对CRS大鼠焦虑行为的影响及机制研究[J]. 现代预防医学, 2021,48(3):520-523.
[2] Yi JH, Jeon J, Kwon HY, et al. Rubrofusarin attenuates chronic restraint stress-induced depressive symptoms[J]. Int J Mol Sci, 2020, 21(10):3454.
[3] Ryo K, Ikuko M, Natsuki K, et al. Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection[J]. Sci Rep, 2020, 10(1):20698.
[4] Mohadeseh G, Shahla N, Behpour Y, et al, Beneficial effects of physical activity and crocin against adolescent stress induced anxiety or depressive-like symptoms and dendritic morphology remodeling in prefrontal cortex in adult male rats[J]. Neurochem Res, 2019, 44(4):917-929.
[5] Rice F, Riglin L, Lomax T, et al. Adolescent and adult differences in major depression symptom profiles[J]. J Affect Disorders, 2019, 243:175-181.
[6] Kwatra M, Ahmed S, Gangipangi VK, et al. Lipopolysaccharide exacerbates chronic restraint stress-induced neurobehavioral deficits:Mechanisms by redox imbalance, ASK1-related apoptosis, autophagic dysregulation[J]. J Psychiatr Res, 2021, 144:462-482.
[7] Dool-Ri O, Ji-Seok Y,Yujin K, et al. Vaccinium bracteatum leaf extract reverses chronic restraint stress-induced depression-like behavior in mice:Regulation of hypothalamic-pituitary-adrenal axis, serotonin turnover systems, and ERK/Akt phosphorylation[J]. Front Pharmacol, 2018, 9:604.
[8] Kyoung SM, Min CC, McIntyre S, et al. Effects of escitalopram and paroxetine on mTORC1 signaling in the rat hippocampus under chronic restraint stress[J]. BMC Neuroscience, 2017, 18(1):39.
[9] Khan AR, Geiger L, Wiborg O, et al. Stress-induced morphological, cellular and molecular changes in the brain-lessons learned from the chronic mild stress model of depression[J]. Cells, 2020,9(4):1026-1026.
[10] Martin KP, Wellman CL. NMDA receptor blockade alters stress-induced dendritic remodeling in medial prefrontal cortex[J]. Cerebral Cortex, 2011, 21(10):2366-2373.
[11] Khadrawya YA, Hosnya EN, Magdy M, et al. Antidepressant effects of curcumin-coated iron oxide nanoparticles in a rat model of depressio[J]. Eur J Pharmacol, 2021, 908:174384.
[12] 郭晓冬,许二平,李琳,等. 加味丹栀逍遥散对抑郁模型大鼠下丘脑内 5-HT 和 NE 的影响[J].中医学报,2013,28 (12):1831-1833.
[13] Liu W,Ge TT, Leng YS, et al. The role of neural plasticity in depression:From hippocampus to prefrontal cortex[J]. Neural Plasticity, 2017, 2017:6871089.
[14] Martinez-Mota L, Cruz-Tavera A,Dorantes-Barrón AM, et al.Calea zacatechichi Schltdl. (Compositae) produces anxiolytic- and antidepressant-like effects, and increases the hippocampal activity during REM sleep in rodents[J]. J Ethnopharmacol, 2021, 265:113316.
[15] Dario A, Graziano P. Animal models of post-traumatic stress disorder and novel treatment targets [J]. Behavl Pharmacol, 2019, 30(2):130-150.
[16] Thapar A, Collishaw S, Pine DS, et al. Depression in adolescence[J]. Lancet, 2012, 379 (9820):1056-1067.